Skip to content

Excavation of onset risk of Alzheimer's disease

Excavation of onset risk of Alzheimer's disease - Excavation of onset risk of Alzheimer's disease

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
JPRN
Registry ID
JPRN-UMIN000017442
Enrollment
1000
Registered
2015-06-01
Start date
2015-10-26
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Mild cognitive impairment (MCI) Healthy adult volunteers

Interventions

None listed

Sponsors

Department of Neurology Oita University Faculty of Medicine
Lead Sponsor
TOSHIBA TDK
Collaborator

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: <Inclusion criteria of MCI> (1)Subject who lives in Usuki city. (2)Willing and able to complete the protocol. (3)MCI who fulfilled the diagnostic criteria of Petersen (CDR 0.5). <Inclusion criteria of healthy adult volunteers> (1)Subject who lives in Usuki city. (2)Willing and able to complete the protocol. (3)Healthy adult volunteers who did not fulfill the diagnostic criteria of Petersen (CDR 0).

Exclusion criteria

Exclusion criteria: Any significant neurologic or psychiatric disease other than MCI (1). History of significant head trauma, alcohol or substance abuse (2,6,7). Any significant systemic illness or unstable medical condition which could lead to difficulty complying with the protocol : diabetes mellitus, thyroid disease, anemia, cardiac disease, or hypertension (3,4,5,10,11). Clinically significant and severe abnormalities in hepatic and/or renal function (8,9). Subjects who participate in another study within 3 months (12). Subjects who donated blood (over 200ml or over 400ml, within 1 month or 3 months, respectively (13). Subjects who are judged to be inadequate for their eligibility by investigators (14).

Design outcomes

Primary

MeasureTime frame
Identification of non-genetic risk factors for onset of AD via analysis of differences between MCI individuals that convert to AD and MCI nonconverters (who have been scanned using PET)

Secondary

MeasureTime frame
Group differences for each imaging and biomarker measurement.

Countries

Japan

Contacts

Public ContactNoriyuki Kimura

Oita University Faculty of Medicine Department of Neurology

noriyuki@oita-u.ac.jp097-586-5814

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026